IL15 and cancer: However, the majority of TNBC patients have a poor prognosis even after combinational chemotherapy and immune checkpoint blockade, due to the low density and poor activity of tumor‐infiltrating lymphocytes (cold tumor).[13] Upregulation of both IL15Rα and IL15 in TNBC cells is sufficient to activate immune cells through paracrine signaling, but it also induces the proliferation of cancer cells.[14] Inspired by the fact that the biologically effective form of IL15 is membrane‐bound IL15c, we present a novel approach in the form of a pH‐responsive macrolittin 70 (pH‐M70)‐modified nanovesicle.